The FDA alerted the public Monday of a recent recall initiated by Gilead Sciences, Inc. of one lot of Veklury® (remdesivir) for Injection due to possible contamination with glass particulate. The company announced the recall on Friday, September 20th, after receiving a complaint from a consumer.
Health care providers typically prescribe the drug Veklury® (remdesivir) for Injection to patients and children who have been hospitalized with Covid-19 or who have been diagnosed with Covid-19 and have risk factors for hospitalization or more serious illness. According to Yale Medicine, Veklury® (remdesivir) is an antiviral medication that decreases hospitalization rates for patients at risk for severe illness and reduces the average length of hospital stays for patients who have already been hospitalized with Covid-19. The drug must be administered intravenously in an inpatient or outpatient hospital setting with close monitoring for reactions.
Gilead Sciences, Inc. is recalling lot # 47035CFA of Veklury® (remdesivir) for Injection 100 mg/vial with an expiration date of 11/2025. The National Drug Code for the medication is 61958-2901-02, and the drug was distributed throughout the United States from July 16, 2024 through August 7, 2024. The medication comes in a small glass bottle, which is then packaged in a white box with the NDC listed in the upper left corner. The medication is distributed to health care providers in powder form and must be reconstituted and diluted prior to injection.
While Gilead Sciences, Inc. has not received any reports of injury linked to contamination of the product, the company has confirmed the presence of glass particulate in the affected lot. The company warns that injecting a medication with glass particulate could cause injuries ranging from swelling and infection to stroke or death if the particulate were to block major blood vessels.
The company has mailed instructions, requesting that health care facilities and distributors stop using and selling Veklury® (remdesivir) from lot # 47035CFA and that they return all relevant vials to Gilead Sciences, Inc.
Consumers can direct all questions about the recall to Gilead Medical Information at 1-866-633-4474, Monday to Friday, 5 am to 6 pm PST. Alternately, the company can be reached through their website at www.askgileadmedical.com.
Patients and health care providers can report any new adverse health events related to Veklury® (remdesivir) for Injection 100 mg/vial through the FDA’s MedWatch Online Voluntary Reporting Form.
If you or a loved one has suffered an injury or adverse health outcome after receiving an injection of Veklury® (remdesivir) for the treatment of Covid-19, we urge you to get in touch with our team. It’s vital that the liable parties be held accountable for their negligence to prevent the further distribution of dangerous medication to health care facilities in the United States. Our experienced attorneys at TruLaw are prepared to learn about your story and help you begin building a case for just compensation. Contact us today or try out our free Instant Case Evaluation ℠ to get started.